ADME-Toxicology Testing

ADME-Toxicology Testing

Global ADME-Toxicology Testing Market to Reach US$18.8 Billion by 2030

The global market for ADME-Toxicology Testing estimated at US$9.1 Billion in the year 2023, is expected to reach US$18.8 Billion by 2030, growing at a CAGR of 10.9% over the analysis period 2023-2030. Cell Culture Technology, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and reach US$9.6 Billion by the end of the analysis period. Growth in the High Throughput Screening Technology segment is estimated at 7.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.2 Billion While China is Forecast to Grow at 14.0% CAGR

The ADME-Toxicology Testing market in the U.S. is estimated at US$4.2 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 14.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.7% and 11.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.2% CAGR.

Global ADME-Toxicology Testing Market - Key Trends and Drivers Summarized

ADME-Toxicology Testing is a critical process in pharmacology, referring to the assessment of Absorption, Distribution, Metabolism, and Excretion (ADME) properties of potential pharmaceutical compounds alongside their toxicological profiles. This type of testing is fundamental in drug development, providing essential data that predicts how substances behave in the body, which can impact drug safety and efficacy. The toxicological tests evaluate potential adverse effects caused by drug candidates, helping to identify any toxic risk associated with drug intake. ADME-Toxicology testing is not only a regulatory requirement but also a crucial step to ensure that only safe and efficacious drugs reach clinical trials and eventually the market, thereby safeguarding public health.

The demand for ADME-Toxicology testing has surged with the expansion of the pharmaceutical industry and the introduction of more complex biologic drugs which require intricate safety assessments. Modern testing methods now often employ sophisticated technologies such as high-throughput screening and molecular modeling to predict ADME-Tox profiles efficiently and accurately. Additionally, the integration of in vitro and in silico models has enhanced the predictive capabilities of these tests, reducing the reliance on animal testing and aligning with the global push towards more ethical research practices. These advancements not only expedite the drug development process but also improve its cost-effectiveness, enabling researchers to screen out potential failures earlier in the development cycle. The increasing complexity of new therapeutic agents, including targeted therapies and personalized medicine, further necessitates the detailed and precise analysis provided by advanced ADME-Tox studies.

The growth in the ADME-Toxicology testing market is driven by several factors. Technological advancements that offer more rapid, accurate, and cost-effective testing methods are a primary driver. As pharmaceutical companies continue to seek ways to reduce the time and cost associated with drug development, these advanced technologies become increasingly attractive. Additionally, regulatory requirements have become more stringent worldwide, demanding more comprehensive toxicity and efficacy data before a drug can be approved. This regulatory landscape ensures continual demand for ADME-Tox testing services. Moreover, the growing focus on personalized medicine and the development of drugs with narrower therapeutic indices call for more detailed and customized toxicity testing, further propelling the market. Finally, the ethical push towards reducing animal testing in drug development encourages the adoption of alternative in vitro and in silico methods, aligning market expansion with broader ethical standards. These factors collectively ensure sustained growth in the ADME-Toxicology testing market, highlighting its critical role in advancing safe and effective pharmaceuticals.

Select Competitors (Total 79 Featured) -

• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Corning, Inc.
• BD Biosciences
• Charles River Laboratories International, Inc.
• AB Sciex LLC
• Dassault Systemes SE (3DS)
• Cyprotex Limited
• BioReliance Corporation
• Crown Bioscience, Inc.
• Envigo, Inc.
• ADMEcell, Inc.
• Endonovo Therapeutics, Inc.
• CN Bio Innovations Ltd.
• Emulate, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.